Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation-Reference-Cited by-同舟云学术

Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

Published:2021-06-09 Issue:10 Volume:56 Page:2464-2470
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Mac Stephanie,Ngo Dat,Yang Dongyun,Chen Jason^ORCID,Ali Haris^ORCID,Arslan Shukaib,Dadwal Sanjeet,Salhotra Amandeep,Cao Thai,Karras Nicole,Aldoss Ibrahim,Koller Paul^ORCID,Artz Andrew^ORCID,Aribi Ahmed,Sandhu Karamjeet^ORCID,Pullarkat Vinod,Stein Anthony,Marcucci Guido,Forman Stephen J.,Nakamura Ryotaro^ORCID,Al Malki Monzr M.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

https://www.nature.com/articles/s41409-021-01364-0.pdf

Reference31 articles.

1. D’Souza A, Fretham C, Lee SJ, Arora M, Brunner J, Chhabra S, et al. Current use of and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2020;26:e177–82.

2. Khan MA, Bashir Q, Chaudhry QU, Ahmed P, Satti TM, Mahmood SK. Review of haploidentical hematopoietic cell transplantation. J Glob Oncol. 2018;4:1–13.

3. Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5:211ra157.

4. Al-Homsi AS, Roy TS, Cole K, Feng Y, Duffner U. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant. 2015;21:604–11.

5. Ruggeri A, Labopin M, Bacigalupo A, Afanasyev B, Cornelissen JJ, Elmaagacli A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT. J Hematol Oncol. 2018;11:40.

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictors of fluid overload in allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide;Journal of Oncology Pharmacy Practice;2024-08-18

2. Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation;Bone Marrow Transplantation;2024-06-14

3. Comparison of Infectious Complications in Patients Receiving High-Dose Cyclophosphamide as GvHD After Transplantation From A 9/10 HLA-Matched Unrelated Donor with Standard GvHD Prophylaxis After Transplant From A Full Matching Donor;Mediterranean Journal of Hematology and Infectious Diseases;2024-02-29

4. Posttransplant cyclophosphamide versus antithymocyte globulin in patients with acute lymphoblastic leukemia treated with allogeneic hematopoietic cell transplantation from matched unrelated donors: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation;Cancer;2023-09

5. Interaction Between High-Dose Intravenous Busulfan and Post-Transplantation Cyclophosphamide on Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplantation;Transplantation and Cellular Therapy;2023-09